First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Phase 1 open-label study to evaluate the safety, tolerability and preliminary efficacy of
bispecific antibody MR001 and to determine the maximal tolerated dose and designate the
recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.